Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma

Aditya Raghunathan, Adriana Olar, Hannes Vogel, John R. Parker, Susan C. Coventry, Robert Debski, Constance T. Albarracin, Kenneth D. Aldape, Daniel P. Cahill, Suzanne Z. Powell, Gregory N. Fuller

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Mutations of isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (R132H), have been described in World Health Organization grade II and III diffuse gliomas and secondary glioblastoma. Immunohistochemistry using a mouse monoclonal antibody has a high specificity and sensitivity for detecting IDH1 R132H mutant protein in sections from formalin-fixed, paraffin-embedded tissue. Angiocentric glioma (AG), a unique neoplasm with mixed phenotypic features of diffuse glioma and ependymoma, has recently been codified as a grade I neoplasm in the 2007 World Health Organization classification of central nervous system tumors. The present study was designed to evaluate IDH1 R132H protein in AG. Three cases of AG were collected, and the diagnoses were confirmed. Expression of mutant IDH1 R132H protein was determined by immunohistochemistry on representative formalin-fixed, paraffin-embedded sections using the antihuman mouse monoclonal antibody IDH1 R132H (Dianova, Hamburg, Germany). Known IDH1 mutation-positive and IDH1 wild-type cases of grade II to IV glioma served as positive and negative controls. All 3 patients were male, aged 3, 5, and 15 years, with intra-axial tumors in the right posterior parietal-occipital lobe, right frontal lobe, and left frontal lobe, respectively. All 3 cases showed characteristic morphologic features of AG, including a monomorphous population of slender bipolar cells that diffusely infiltrated cortical parenchyma and ensheathed cortical blood vessels radially and longitudinally. All 3 cases were negative for the presence of IDH1 R132H mutant protein (0/3). All control cases showed appropriate reactivity. IDH1 R132H mutation has been described as a common molecular signature of grade II and III diffuse gliomas and secondary glioblastoma; however, AG, which exhibits some features of diffuse glioma, has not been evaluated. The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma.

Original languageEnglish (US)
Pages (from-to)255-259
Number of pages5
JournalAnnals of Diagnostic Pathology
Volume16
Issue number4
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Isocitrate Dehydrogenase
Glioma
Mutation
Genes
Frontal Lobe
Mutant Proteins
Glioblastoma
Paraffin
Formaldehyde
Neoplasms
Immunohistochemistry
Monoclonal Antibodies
Ependymoma
Occipital Lobe
Central Nervous System Neoplasms
Parietal Lobe
Proteins
Histidine
Germany
Blood Vessels

Keywords

  • Angiocentric glioma
  • IDH1
  • IDH1 R132H immunostain
  • mIDH1R132H

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. / Raghunathan, Aditya; Olar, Adriana; Vogel, Hannes; Parker, John R.; Coventry, Susan C.; Debski, Robert; Albarracin, Constance T.; Aldape, Kenneth D.; Cahill, Daniel P.; Powell, Suzanne Z.; Fuller, Gregory N.

In: Annals of Diagnostic Pathology, Vol. 16, No. 4, 01.08.2012, p. 255-259.

Research output: Contribution to journalArticle

Raghunathan, A, Olar, A, Vogel, H, Parker, JR, Coventry, SC, Debski, R, Albarracin, CT, Aldape, KD, Cahill, DP, Powell, SZ & Fuller, GN 2012, 'Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma', Annals of Diagnostic Pathology, vol. 16, no. 4, pp. 255-259. https://doi.org/10.1016/j.anndiagpath.2011.11.003
Raghunathan, Aditya ; Olar, Adriana ; Vogel, Hannes ; Parker, John R. ; Coventry, Susan C. ; Debski, Robert ; Albarracin, Constance T. ; Aldape, Kenneth D. ; Cahill, Daniel P. ; Powell, Suzanne Z. ; Fuller, Gregory N. / Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. In: Annals of Diagnostic Pathology. 2012 ; Vol. 16, No. 4. pp. 255-259.
@article{fa70682db45447d4a44057860a87b27c,
title = "Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma",
abstract = "Mutations of isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (R132H), have been described in World Health Organization grade II and III diffuse gliomas and secondary glioblastoma. Immunohistochemistry using a mouse monoclonal antibody has a high specificity and sensitivity for detecting IDH1 R132H mutant protein in sections from formalin-fixed, paraffin-embedded tissue. Angiocentric glioma (AG), a unique neoplasm with mixed phenotypic features of diffuse glioma and ependymoma, has recently been codified as a grade I neoplasm in the 2007 World Health Organization classification of central nervous system tumors. The present study was designed to evaluate IDH1 R132H protein in AG. Three cases of AG were collected, and the diagnoses were confirmed. Expression of mutant IDH1 R132H protein was determined by immunohistochemistry on representative formalin-fixed, paraffin-embedded sections using the antihuman mouse monoclonal antibody IDH1 R132H (Dianova, Hamburg, Germany). Known IDH1 mutation-positive and IDH1 wild-type cases of grade II to IV glioma served as positive and negative controls. All 3 patients were male, aged 3, 5, and 15 years, with intra-axial tumors in the right posterior parietal-occipital lobe, right frontal lobe, and left frontal lobe, respectively. All 3 cases showed characteristic morphologic features of AG, including a monomorphous population of slender bipolar cells that diffusely infiltrated cortical parenchyma and ensheathed cortical blood vessels radially and longitudinally. All 3 cases were negative for the presence of IDH1 R132H mutant protein (0/3). All control cases showed appropriate reactivity. IDH1 R132H mutation has been described as a common molecular signature of grade II and III diffuse gliomas and secondary glioblastoma; however, AG, which exhibits some features of diffuse glioma, has not been evaluated. The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma.",
keywords = "Angiocentric glioma, IDH1, IDH1 R132H immunostain, mIDH1R132H",
author = "Aditya Raghunathan and Adriana Olar and Hannes Vogel and Parker, {John R.} and Coventry, {Susan C.} and Robert Debski and Albarracin, {Constance T.} and Aldape, {Kenneth D.} and Cahill, {Daniel P.} and Powell, {Suzanne Z.} and Fuller, {Gregory N.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.anndiagpath.2011.11.003",
language = "English (US)",
volume = "16",
pages = "255--259",
journal = "Annals of Diagnostic Pathology",
issn = "1092-9134",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma

AU - Raghunathan, Aditya

AU - Olar, Adriana

AU - Vogel, Hannes

AU - Parker, John R.

AU - Coventry, Susan C.

AU - Debski, Robert

AU - Albarracin, Constance T.

AU - Aldape, Kenneth D.

AU - Cahill, Daniel P.

AU - Powell, Suzanne Z.

AU - Fuller, Gregory N.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Mutations of isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (R132H), have been described in World Health Organization grade II and III diffuse gliomas and secondary glioblastoma. Immunohistochemistry using a mouse monoclonal antibody has a high specificity and sensitivity for detecting IDH1 R132H mutant protein in sections from formalin-fixed, paraffin-embedded tissue. Angiocentric glioma (AG), a unique neoplasm with mixed phenotypic features of diffuse glioma and ependymoma, has recently been codified as a grade I neoplasm in the 2007 World Health Organization classification of central nervous system tumors. The present study was designed to evaluate IDH1 R132H protein in AG. Three cases of AG were collected, and the diagnoses were confirmed. Expression of mutant IDH1 R132H protein was determined by immunohistochemistry on representative formalin-fixed, paraffin-embedded sections using the antihuman mouse monoclonal antibody IDH1 R132H (Dianova, Hamburg, Germany). Known IDH1 mutation-positive and IDH1 wild-type cases of grade II to IV glioma served as positive and negative controls. All 3 patients were male, aged 3, 5, and 15 years, with intra-axial tumors in the right posterior parietal-occipital lobe, right frontal lobe, and left frontal lobe, respectively. All 3 cases showed characteristic morphologic features of AG, including a monomorphous population of slender bipolar cells that diffusely infiltrated cortical parenchyma and ensheathed cortical blood vessels radially and longitudinally. All 3 cases were negative for the presence of IDH1 R132H mutant protein (0/3). All control cases showed appropriate reactivity. IDH1 R132H mutation has been described as a common molecular signature of grade II and III diffuse gliomas and secondary glioblastoma; however, AG, which exhibits some features of diffuse glioma, has not been evaluated. The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma.

AB - Mutations of isocitrate dehydrogenase-1 gene (IDH1), most commonly resulting in replacement of arginine at position 132 by histidine (R132H), have been described in World Health Organization grade II and III diffuse gliomas and secondary glioblastoma. Immunohistochemistry using a mouse monoclonal antibody has a high specificity and sensitivity for detecting IDH1 R132H mutant protein in sections from formalin-fixed, paraffin-embedded tissue. Angiocentric glioma (AG), a unique neoplasm with mixed phenotypic features of diffuse glioma and ependymoma, has recently been codified as a grade I neoplasm in the 2007 World Health Organization classification of central nervous system tumors. The present study was designed to evaluate IDH1 R132H protein in AG. Three cases of AG were collected, and the diagnoses were confirmed. Expression of mutant IDH1 R132H protein was determined by immunohistochemistry on representative formalin-fixed, paraffin-embedded sections using the antihuman mouse monoclonal antibody IDH1 R132H (Dianova, Hamburg, Germany). Known IDH1 mutation-positive and IDH1 wild-type cases of grade II to IV glioma served as positive and negative controls. All 3 patients were male, aged 3, 5, and 15 years, with intra-axial tumors in the right posterior parietal-occipital lobe, right frontal lobe, and left frontal lobe, respectively. All 3 cases showed characteristic morphologic features of AG, including a monomorphous population of slender bipolar cells that diffusely infiltrated cortical parenchyma and ensheathed cortical blood vessels radially and longitudinally. All 3 cases were negative for the presence of IDH1 R132H mutant protein (0/3). All control cases showed appropriate reactivity. IDH1 R132H mutation has been described as a common molecular signature of grade II and III diffuse gliomas and secondary glioblastoma; however, AG, which exhibits some features of diffuse glioma, has not been evaluated. The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma.

KW - Angiocentric glioma

KW - IDH1

KW - IDH1 R132H immunostain

KW - mIDH1R132H

UR - http://www.scopus.com/inward/record.url?scp=84864125590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864125590&partnerID=8YFLogxK

U2 - 10.1016/j.anndiagpath.2011.11.003

DO - 10.1016/j.anndiagpath.2011.11.003

M3 - Article

C2 - 22445362

AN - SCOPUS:84864125590

VL - 16

SP - 255

EP - 259

JO - Annals of Diagnostic Pathology

JF - Annals of Diagnostic Pathology

SN - 1092-9134

IS - 4

ER -